Steven Fruchtman

Steven Fruchtman

Company: Onconova Therpaeutics

Job title: President & Chief Executive Officer


Panel Discussion: Empowering Combination Strategies to Target RAS Mutant Cancers: The Future of Oncology Therapy 2:00 pm

What are the key factors to consider ensuring successful translation from discovery to clinic? The importance of moving beyond G12C – with the abundance of research surrounding G12C mutation, how and why should we be pushing for new avenues to explore? Technology, platforms & collaborations – what does the RAS community need in order to…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.